Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF
  • Original article
  • Published:

Relation between serum visfatin and clinical severity in different stages of rheumatoid arthritis

Egyptian Rheumatology and Rehabilitation volume 40, pages 1–8 (2013)Cite this article

Abstract

Objective

Visfatin is one of the recently discovered adipokines that plays important proinflammatory and catabolic roles in rheumatoid arthritis (RA). Proinflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-15, IL-18, and tumor necrosis factor-α (TNF-α), induce a number of physiological changes that result in the characteristic signs of inflammation. As inflammation is the major factor leading to structural damage, it is critical to achieve rapid suppression of inflammation to maximize disease control. Therefore, early diagnosis and treatment of RA is of paramount importance. As information on the relation between visfatin and disease activity in RA patients is conflicting and little is known about its role in joint damage, the present study was designed to evaluate the role of serum visfatin as a recent proinflammatory marker in RA according to the activity scores of disease to assess the possibility of introducing serum visfatin in the diagnosis and monitoring of RA patients and to determine the correlation between its serum level and other cytokines (IL-6 and TNF-α) and other laboratory biomarkers.

Patients and methods

This study was carried out on a total of 80 individuals; 60 of these were (48 women, 80%, 12 men, 20%) diagnosed with RA according to the American College of Rheumatology/The European League Against Rheumatism 2010 criteria and 20 healthy individuals were included as controls (10 women, 50%, 10 men, 50%). RA patients were classified into three groups: group I (severe RA) included 20 RA patients, group II (moderate RA) included 20 RA patients, and group III (mild RA) included 20 RA patients according to clinical evaluation for disease activity assessed using a 28 joint disease activity score (DAS-28). Blood samples were obtained from patients and controls for complete blood count and erythrocyte sedimentation rate. The sera of patients were collected for enzyme-linked immunosorbent assay estimation of serum visfatin, IL-6, and TNF-α. C-reactive protein (CRP) and rheumatoid factor (RF) were determined using the turbidimetry quantitative method.

Results

Comparison of the RA and control groups showed that the mean serum levels of visfatin, platelets (PLT), ESR, IL-6, CRP, and RF were significantly higher in RA patients than in the control group. Comparison of the mild, moderate, and severe RA groups showed that the mean levels of visfatin and IL-6 were significantly higher in the severe RA group than the moderate RA group, which was significantly higher than that of the mild RA group. There was a significant positive correlation between serum visfatin and IL-6, ESR, CRP, TNF-α, and DAS-28 in the RA group.

Conclusion

Visfatin plays a role in the pathogenesis of RA and could be considered as a disease marker in RA and a marker of joint damage and hence as a potential therapeutic target for RA. The findings of the present study also indicate that serum visfatin and IL-6 might be of diagnostic value for RA; however, the combined diagnosis using serum visfatin, IL-6, and the RF test can improve the diagnosis of RA in the early stage. Further studies are required to determine the possibility of introducing visfatin as a potential therapeutic target especially in early RA to prevent erosions.

References

  1. Hoffmann M, Hayer S, Steiner G. Immunopathogenesis of rheumatoid arthritis. Ann N Y Acad Sci 2009; 1173:391–400.

    Article  CAS  PubMed  Google Scholar 

  2. Brentano F, Kyburz D, Schorr O. The role of Toll-like receptor signaling in the pathogenesis of arthritis. Cell Immunol 2005; 233:90–96.

    Article  CAS  PubMed  Google Scholar 

  3. Moreland LW, Bridges SL. Early rheumatoid arthritis: a medical emergency? Am J Med 2001; 111:498–500.

    Article  CAS  PubMed  Google Scholar 

  4. Mota LM, Laurindo IM, Santos Neto LL. Early rheumatoid arthritis: concepts. Rev Assoc Med Bras 2010; 56:227–229.

    Article  PubMed  Google Scholar 

  5. Matsui H, Tsutsumi A, Sugihara M, Suzuki T, Iwanami K, Kohno M, et al. Visfatin (pre-B cell colonyenhancing factor) gene expression in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:571–572.

    Article  CAS  PubMed  Google Scholar 

  6. Luk T, Malam Z, Marshall J. Pre-B cell colony enhancing factor (PBEF)/ visfatin: a novel media innate immunity. J Leukoc Biol 2008; 83:804–816.

    Article  CAS  PubMed  Google Scholar 

  7. Fukuhara A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426–430.

    Article  CAS  PubMed  Google Scholar 

  8. Moschen AR, Kaser A, Enrich B. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178:1748–1758.

    Article  CAS  PubMed  Google Scholar 

  9. Rho YH, Solus J, Sokka T. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009; 60:1906–1914.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Busso N, Karababa M, Nobile M. Pharmacological inhibition of nicotinamide phosphoribosyl-transferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008; 3:2267.

    Google Scholar 

  11. Fionula H. Evidence that cytokines plays a role in rheumatoid arthritis. J Clin Invest 2008; 118:3537–3545.

    Article  CAS  Google Scholar 

  12. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118:3537–3545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011. doi: 10.1155/2011/765624.

  14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism 2010; 62:2569–2581.

    PubMed  Google Scholar 

  15. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2: 175–184.

    Article  CAS  PubMed  Google Scholar 

  16. Fransen J, Van Riel CM. The DAS and the EULAR response criteria. Clin Exp Rheumatol 2005; 23:S93–S99.

    CAS  PubMed  Google Scholar 

  17. Bray GA. Overweight is risking factor: definition, classification, prevalence, and risk. Ann N Y Acad Sci 1987; 499:14–28.

    Article  CAS  PubMed  Google Scholar 

  18. Otsuji S, Shibata H, Umeda M. Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 1982; 28:2121–2124.

    Article  CAS  PubMed  Google Scholar 

  19. Winkles JW, Lunec J, Gray L. Automated enhanced latex agglutination assay for RF in serum. Clin Chem 1989; 35:303–307.

    Article  CAS  PubMed  Google Scholar 

  20. Mesri M. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161:4382–4387.

    CAS  PubMed  Google Scholar 

  21. Grimsholm O, Rantapöö-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Research & Therapy 2008; 10:410.

    Article  CAS  Google Scholar 

  22. Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research. 4th ed. Oxford: Blackwell Science; 2002.

  23. Carrasco R, Barton A. Biomarkers of outcome in rheumatoid arthritis. Rheumatology Reports 2010; 2 (e3): 26–38.

    CAS  Google Scholar 

  24. Visser K. Optimal dosage and route of administration of metho-trexate in rheumatoid arthritis. Ann Rheum Dis 2005; 68:1094–1099.

    Article  CAS  Google Scholar 

  25. Iain B McInnes, Schett G. Cytokines in the pathogenesis of RA. Immunology 2007; 7:429–442.

    CAS  PubMed  Google Scholar 

  26. Bao JP, Chen WP, Wu LD. Visfatin; a potential therapeutic target for rheumatoid arthritis. J Int Med Res 2009; 37:1655–1661.

    Article  CAS  PubMed  Google Scholar 

  27. Jian LIU, Rui-kai Z, Xue-fang YU, Yuan W. Effects of Xinfeng capsule on platelet parameters, p-select, platelet ultra-structure and its therapeutic effect on rheumatoid arthritis patients in active phase. China J Chinese Med 2008;12–16.

  28. Gülsüm S. Increased platelet activation markers in rheumatoid arthritis are they related with subclinical atherosclerosis? Platelets 2008; 19:146–154.

    Article  CAS  Google Scholar 

  29. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KMJ, Kitas GD. Platelet functions in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2010; 31:153–164.

    Article  CAS  Google Scholar 

  30. Areskoug ED. A literature review of the sexual health of women with RA. Musculoskeletal Care 2009; 7:219–226.

    Article  Google Scholar 

  31. Brentano F, Schorr O, Ospelt C. Pre-B cell colony-enhancing factor/ visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56:2829–2839.

    Article  CAS  PubMed  Google Scholar 

  32. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, Gualillo O. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1198–1201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Nowell M, Richards P, Fielding C. Regulation of pre-B cell colony enhancing factor by STAT 3-dependent interleukin-6 Trans signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006; 54:2084–2095.

    Article  CAS  PubMed  Google Scholar 

  34. Senolt L, Kryštůfková O, Hulejová H. The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine 2011; 55:116–121.

    Article  CAS  PubMed  Google Scholar 

  35. Nam J, Villeneuve E, Emery P. The role of biomarkers in the management of patients with RA. Curr Rheumatol Rep 2009; 11:371–377.

    Article  CAS  PubMed  Google Scholar 

  36. Nalesnik M, Nikolić JM, Jandrić S. ADA and CRP in diagnosing and monitoring of RA. Med Glas Ljek komore Zenicko-doboj kantona 2011; 8:163–168.

    Google Scholar 

  37. Al-mesry MR, Attwa ET, Omar HM. Assessment of cardiovascular risk factors in RA and OA. Egypt Rheumatol Rehabil 2003; 30:323–332.

    Google Scholar 

  38. Morovic-Vergles J, Culo MI, Gamulin S, Culo F. Cyclic adenosine 50-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheumatol Int 2008; 29:167–171.

    Article  CAS  PubMed  Google Scholar 

  39. Singh U. Is rheumatoid factor still a superior test for the diagnosis of RA? Rheumatol Int 2010; 30:1115–1119.

    Article  CAS  PubMed  Google Scholar 

  40. Novikov AA, Aleksandrova EN, Karateev DE, Luchikhina EL, Demidova NV, Cherkasova MV, et al. Diagnostic value of antibodies to modified citrullinizedvimentin in early rheumatoid arthritis. Klin Lab Diagn 2008; 27–29.

  41. Khalifa AIM, Abdelfattah A. Anti CCP2 and anti keratin antibodies in patients with RA and OA. Egyptian Soc Rheumatol Rehabil 2008; 35:1–10.

    Google Scholar 

  42. Hui L, Wuqi S, Yang L. Diagnostic value of anti-CCP antibodies in northern Chinese Han patients with RA and its correlation with disease activity. Clin Rheumatol 2010; 29:413–417.

    Article  Google Scholar 

  43. Murakami Miho, Nishimoto Norihiro. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011; 23:273–277.

    Article  CAS  PubMed  Google Scholar 

  44. Fonseca JE, Santos MJ. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8:538–542.

    Article  CAS  PubMed  Google Scholar 

  45. Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65:11–15.

    Google Scholar 

  46. Katz Y. Interleukin-17 enhances tumor necrosis factor induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts. Arthritis Rheum 2001; 44:2176–2184.

    Article  CAS  PubMed  Google Scholar 

  47. Sue-Yun Hwang. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004; 6:R120–R128.

  48. Klarenbeek NB, Koevoets R, van der Heijde DM, Gerards AH, Ten Wolde S, Kerstens PJ, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011; 70:1815–1821.

    Article  CAS  PubMed  Google Scholar 

  49. Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011; 63:2567–2574.

    Article  CAS  PubMed  Google Scholar 

  50. Gonzalez-Gay M, Vazquez-Rodriguez T, Garcia-Unzueta M. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-a therapy. Clin Exp Rheumatol 2010; 28:56–62.

    CAS  PubMed  Google Scholar 

  51. Gosset M, Berenbaum F, Salvat C. Crucial role of visfatin in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 2008; 58:1399–1409.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Faculty of Pharmacy (girls), Physical Medicine and Rehabilitation, AL-Azhar University, 200 Shubrast, Cairo, Egypt

    Abeer Ibrahim

  2. Department of Rheumatology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

    Ismail Ashraf Khalifa MD, MSc

  3. Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

    Abdelhameed Abdelfattah

Authors
  1. Ismail Ashraf Khalifa MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abeer Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdelhameed Abdelfattah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ismail Ashraf Khalifa MD, MSc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khalifa, I.A., Ibrahim, A. & Abdelfattah, A. Relation between serum visfatin and clinical severity in different stages of rheumatoid arthritis. Egypt Rheumatol Rehabil 40, 1–8 (2013). https://doi.org/10.7123/01.ERR.0000426439.58259.f6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.7123/01.ERR.0000426439.58259.f6

Keywords